Prognostic Significance of Reduction in Ki67 Index After Neoadjuvant Chemotherapy in Patients With Breast Cancer in Kerman Between 2009 And 2014

por Moazed, Vahid, Jafari, Elham, Kalantari Khandani, Behjat, Nemati, Ali, Roozdar, Alale, Ben Razavi, Seyyed Amir
Publicado 2018

An Investigation of the Risk Factors of Osteoporosis and the Correlation between Opium Consumption and Osteoporosis in Adults

por Heydari, Zeynab, Shahesmaeili, Armita, Khajeh-Bahrami, Mohammad Reza, Rezazadeh-Mehrizi, Mandana, Gozashti, Mohammad Hossein, Moazed, Vahid
Publicado 2017

Conjugated Estrogen in Late-Onset Hemorrhagic Cystitis Associated with Hematopoietic Stem Cell Transplantation

por Mousavi, Seyed Asadollah, Moazed, Vahid, Mohebbi, Niayesh, Hadjibabaie, Molouk, Alimoghaddam, Kamran, Bahar, Babak, Jahani, Mohammad, Ghavamzadeh, Ardeshir
Publicado 2017

Copper and Zinc Levels in Myelodysplastic Syndrome Patients versus Healthy Subjects

por Moazed, Vahid, Jafari, Elham, Rashidi Nezhad, Bita, Kalantari-Khandani, Behjat, Nemati, Ali, Naghibzadeh Tahami, Ahmad, Mangeli, Foroogh
Publicado 2020

Opium Use and Head and Neck Cancers: A Matched Case-Control Study in Iran

por Alizadeh, Hosniyeh, Naghibzadeh-Tahami, Ahmad, Khanjani, Narges, Yazdi-Feyzabadi, Vahid, Eslami, Hadi, Borhaninejad, Vahidreza, Larizadeh, Mohammad Hasan, Enhesari, Ahmad, Abbasi-Rayeni, Reza, Moazed, Vahid, Arabi Mianroodi, Aliasghar
Publicado 2020

A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab re...

por Nodehi, Reza Safaei, Kalantari, Behjat, Raafat, Jahangir, Ansarinejad, Nafiseh, Moazed, Vahid, Mortazavizadeh, Seyed Mohammad Reza, Hosseinzadeh, Mehran, Ghaderi, Bayazid, Jenabian, Arash, Qadyani, Mojtaba, Haghighat, Shirin, Allahyari, Abolghasem, Mirzania, Mehrzad, Seghatoleslami, Mohammad, Payandeh, Mehrdad, Alikhasi, Afsaneh, Kafi, Hamidreza, Shahi, Farhad
Publicado 2022

Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency cl...

por Allahyari, Abolghasem, Ehsanpour, Ali, Ansarinejad, Nafiseh, Mehrzad, Valiollah, Kalantari, Behjat, Raafat, Jahangir, Ghadiany, Mojtaba, Shahi, Farhad, Gharib, Behrooz, Moazed, Vahid, Khosravi, Adnan, Mirpour, Mir Hossein, Salari, Sina, Mortazavizadeh, Seyedmohammadreza, Nekoyi, Amirabbas, Khani, Mohsen, Sadeghi, Alireza, Gharib, Sirus, Bary, Alireza, Mirzania, Mehrzad, Haghighat, Shirin, Razavi, Seyed Mohsen, Emami, Seyed Amir Hossein, Hosseinzadeh, Mehran, Mirbolouk, Mahdi, Sadighi, Sanambar, Shahrasbi, Abdolali, Esfahani, Ali, Gity, Masoumeh, Anjidani, Nassim, Kafi, Hamidreza, Najafi, Safa
Publicado 2022

Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, eq...

por Allahyari, Abolghasem, Ehsanpour, Ali, Najafi, Behrouz, Ansarinejad, Nafseh, Mehrzad, Valiollah, Kalantari, Behjat, Raafat, Jahangir, Ghadiany, Mojtaba, Shahi, Farhad, Gharib, Behrooz, Moazed, Vahid, Khosravi, Adnan, Mirpour, Mir Hossein, Salari, Sina, Mortazavizadeh, Seyedmohammadreza, Nekoyi, Amirabbas, Khani, Mohsen, Sadeghi, Alireza, Gharib, Sirus, Bary, Alireza, Mirzania, Mehrzad, Haghighat, Shirin, Razavi, Seyed Mohsen, Emami, Seyed Amir Hossein, Hosseinzadeh, Mehran, Mirbolouk, Mahdi, Sadighi, Sanambar, Shahrasbi, Abdolali, Esfahani, Ali, Gity, Masoumeh, Anjidani, Nassim, Kaf, Hamidreza, Najaf, Safa
Publicado 2022